Correction

In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant gram-negative bacilli (Antimicrobial Agents and Chemotherapy (2018) 62:8 (e00533-18) DOI: 10.1128/AAC.02576-17)

Suzannah M. Schmidt-Malan, Avisya J. Mishra, Ammara Mushtaq, Cassandra L. Brinkman, Robin Patel

Research output: Contribution to journalComment/debate

Abstract

Isolate IDRL-10579 in Supplemental Table S2 is Pseudomonas aeruginosa but was mistakenly reported as Klebsiella pneumoniae; the isolate should be listed in Table S2 under P. aeruginosa containing a KPC genetic resistance mechanism. Accordingly, in the 1st paragraph of Materials and Methods, of the 177 isolates which are carbapenemase positive, 118 (not 119) are K. pneumoniae and 5 (not 4) are P. aeruginosa. Also, in Supplemental Table S4, there are 85 (not 86) isolates which are K. pneumoniae complex and 2 (not 1) isolates which are P. aeruginosa. Revised versions of these two supplemental tables have been posted online. In addition, the KPC gene-positive section of Table 2 has been revised as shown below due to an error in the cumulative MIC results. Accordingly, in the Results section, in the 1st paragraph of “Carbapenemase gene-positive isolates,” 3% (not 5%) of the KPC-positive isolates were susceptible to imipenem, 2% (not 3%) were susceptible to cefepime, 1% (not 2%) were susceptible to ceftriaxone, and 3% (not 4%) were susceptible to ceftolozane-tazobactam. In the 3rd paragraph of the Discussion section, 95% (not 93%) of the KPC-positive isolates were resistant to imipenem alone.

Original languageEnglish (US)
Article numbere02563-18
JournalAntimicrobial Agents and Chemotherapy
Volume63
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Imipenem
Anti-Infective Agents
Pseudomonas aeruginosa
Bacillus
Klebsiella pneumoniae
Drug Therapy
Ceftriaxone
Genes
tazobactam drug combination ceftolozane
In Vitro Techniques
MK-7655
carbapenemase

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Correction : In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant gram-negative bacilli (Antimicrobial Agents and Chemotherapy (2018) 62:8 (e00533-18) DOI: 10.1128/AAC.02576-17). / Schmidt-Malan, Suzannah M.; Mishra, Avisya J.; Mushtaq, Ammara; Brinkman, Cassandra L.; Patel, Robin.

In: Antimicrobial Agents and Chemotherapy, Vol. 63, No. 2, e02563-18, 01.02.2019.

Research output: Contribution to journalComment/debate

@article{f9138532021c45c9bb25a3c78a855292,
title = "Correction: In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant gram-negative bacilli (Antimicrobial Agents and Chemotherapy (2018) 62:8 (e00533-18) DOI: 10.1128/AAC.02576-17)",
abstract = "Isolate IDRL-10579 in Supplemental Table S2 is Pseudomonas aeruginosa but was mistakenly reported as Klebsiella pneumoniae; the isolate should be listed in Table S2 under P. aeruginosa containing a KPC genetic resistance mechanism. Accordingly, in the 1st paragraph of Materials and Methods, of the 177 isolates which are carbapenemase positive, 118 (not 119) are K. pneumoniae and 5 (not 4) are P. aeruginosa. Also, in Supplemental Table S4, there are 85 (not 86) isolates which are K. pneumoniae complex and 2 (not 1) isolates which are P. aeruginosa. Revised versions of these two supplemental tables have been posted online. In addition, the KPC gene-positive section of Table 2 has been revised as shown below due to an error in the cumulative MIC results. Accordingly, in the Results section, in the 1st paragraph of “Carbapenemase gene-positive isolates,” 3{\%} (not 5{\%}) of the KPC-positive isolates were susceptible to imipenem, 2{\%} (not 3{\%}) were susceptible to cefepime, 1{\%} (not 2{\%}) were susceptible to ceftriaxone, and 3{\%} (not 4{\%}) were susceptible to ceftolozane-tazobactam. In the 3rd paragraph of the Discussion section, 95{\%} (not 93{\%}) of the KPC-positive isolates were resistant to imipenem alone.",
author = "Schmidt-Malan, {Suzannah M.} and Mishra, {Avisya J.} and Ammara Mushtaq and Brinkman, {Cassandra L.} and Robin Patel",
year = "2019",
month = "2",
day = "1",
doi = "10.1128/AAC.02563-18",
language = "English (US)",
volume = "63",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Correction

T2 - In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant gram-negative bacilli (Antimicrobial Agents and Chemotherapy (2018) 62:8 (e00533-18) DOI: 10.1128/AAC.02576-17)

AU - Schmidt-Malan, Suzannah M.

AU - Mishra, Avisya J.

AU - Mushtaq, Ammara

AU - Brinkman, Cassandra L.

AU - Patel, Robin

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Isolate IDRL-10579 in Supplemental Table S2 is Pseudomonas aeruginosa but was mistakenly reported as Klebsiella pneumoniae; the isolate should be listed in Table S2 under P. aeruginosa containing a KPC genetic resistance mechanism. Accordingly, in the 1st paragraph of Materials and Methods, of the 177 isolates which are carbapenemase positive, 118 (not 119) are K. pneumoniae and 5 (not 4) are P. aeruginosa. Also, in Supplemental Table S4, there are 85 (not 86) isolates which are K. pneumoniae complex and 2 (not 1) isolates which are P. aeruginosa. Revised versions of these two supplemental tables have been posted online. In addition, the KPC gene-positive section of Table 2 has been revised as shown below due to an error in the cumulative MIC results. Accordingly, in the Results section, in the 1st paragraph of “Carbapenemase gene-positive isolates,” 3% (not 5%) of the KPC-positive isolates were susceptible to imipenem, 2% (not 3%) were susceptible to cefepime, 1% (not 2%) were susceptible to ceftriaxone, and 3% (not 4%) were susceptible to ceftolozane-tazobactam. In the 3rd paragraph of the Discussion section, 95% (not 93%) of the KPC-positive isolates were resistant to imipenem alone.

AB - Isolate IDRL-10579 in Supplemental Table S2 is Pseudomonas aeruginosa but was mistakenly reported as Klebsiella pneumoniae; the isolate should be listed in Table S2 under P. aeruginosa containing a KPC genetic resistance mechanism. Accordingly, in the 1st paragraph of Materials and Methods, of the 177 isolates which are carbapenemase positive, 118 (not 119) are K. pneumoniae and 5 (not 4) are P. aeruginosa. Also, in Supplemental Table S4, there are 85 (not 86) isolates which are K. pneumoniae complex and 2 (not 1) isolates which are P. aeruginosa. Revised versions of these two supplemental tables have been posted online. In addition, the KPC gene-positive section of Table 2 has been revised as shown below due to an error in the cumulative MIC results. Accordingly, in the Results section, in the 1st paragraph of “Carbapenemase gene-positive isolates,” 3% (not 5%) of the KPC-positive isolates were susceptible to imipenem, 2% (not 3%) were susceptible to cefepime, 1% (not 2%) were susceptible to ceftriaxone, and 3% (not 4%) were susceptible to ceftolozane-tazobactam. In the 3rd paragraph of the Discussion section, 95% (not 93%) of the KPC-positive isolates were resistant to imipenem alone.

UR - http://www.scopus.com/inward/record.url?scp=85060829338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060829338&partnerID=8YFLogxK

U2 - 10.1128/AAC.02563-18

DO - 10.1128/AAC.02563-18

M3 - Comment/debate

VL - 63

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

M1 - e02563-18

ER -